Key facts
- This page summarizes Valerie Odegard's Form 4 filing for Silverback Therapeutics, Inc. (SPRY).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 May 2022, 17:12.
Valerie Odegard - 02 May 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)
- Reporting relationship
- President and CSO
- Issuer ticker
- SPRY
- Reported as of
- 02 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 May 2022, 17:12:32 UTC
- Prior SEC filing
- 02 Feb 2022
- Next SEC filing
- 07 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey C. Pepe, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Valerie Odegard filed Form 4 for Silverback Therapeutics, Inc. (SPRY) on 04 May 2022.
Change
- Previous filing in this sequence was filed on 02 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +45,233
- Change %
- +276%
- Price
- $0.000000
- Shares after
- 61,639
- Date
- 02 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +90,467
- Change %
- Price
- $0.000000
- Shares after
- 90,467
- Date
- 02 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,467
- Exercise price
- $3.15
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The shares subject to the option will vest on May 2, 2023.